Sintilimab
- Generic Name
- Sintilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2072873-06-2
- Unique Ingredient Identifier
- 8FU7FQ8UPK
- Associated Conditions
- -
- Associated Therapies
- -
TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT04297280
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04279379
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, China
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2023-07-06
- Target Recruit Count
- 47
- Registration Number
- NCT04267549
- Locations
- 🇨🇳
Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 36
- Registration Number
- NCT04263870
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 20
- Registration Number
- NCT04252365
Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04231370
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, China
Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT04220944
- Locations
- 🇨🇳
Department of Interventional Radiology, Zhongshan Hospital, Fudan University., Shanghai, Shanghai, China
Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 60
- Registration Number
- NCT04213170
- Locations
- 🇨🇳
Sun Yat-sen University of Cancer Center, Guangzhou, Guangdong, China
The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer
- First Posted Date
- 2019-12-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Wuhan University
- Target Recruit Count
- 40
- Registration Number
- NCT04212598
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2019-12-19
- Lead Sponsor
- Peking University
- Target Recruit Count
- 80
- Registration Number
- NCT04202601
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath